AntoniRibasMD

Hematology • Los Angeles, CA

Professor, Medicine, UCLA School of Medicine

Join to view full profile

Dr. Ribas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ribas' full profile

Already have an account?

Office
100 Med Plz
Ste 550
Los Angeles, CA 90095

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Universidad de Barcelona Faculty of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 2001 - 2025

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2009

Clinical Trials

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma Start of enrollment: 2004 Feb 01
Completed
Phase 2
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery Start of enrollment: 2004 Apr 01
Completed
Phase 1
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy Start of enrollment: 2004 Dec 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma Start of enrollment: 2005 Jan 01
Completed
Phase 2
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma Start of enrollment: 2007 Jan 01
Completed
Phase 2
Safety Study of CALAA-01 to Treat Solid Tumor Cancers Start of enrollment: 2008 May 01
Terminated
Phase 1
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma Start of enrollment: 2009 Oct 13
Completed
Phase 2
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma Start of enrollment: 2013 Nov 05
Terminated
Phase 1
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies Start of enrollment: 2014 Jul 17
Terminated
Phase 1
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Start of enrollment: 2015 Jan 01
Withdrawn
Phase 2
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 Start of enrollment: 2017 Jan 03
Completed
Phase 1
PET Imaging of the Immune System Using Analog Probes Start of enrollment: 2018 Apr 10
Completed
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Start of enrollment: 2020 Dec 03
Recruiting
Phase 2
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer Start of enrollment: 2017 Jul 26
Terminated
Phase 1
Roles: Contact
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Start of enrollment: 2019 Nov 27
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

4863 citations
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma Taylor
Nature. 2014-11-27
176 citations
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi, Xiangju Kong, Antoni Ribas, Roger S. Lo
Cancer Research. 2011-08-01
111 citations
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Arnav Mehta, Yeon Joo Kim, Lidia Robert, Jennifer Tsoi, Begoña Comin-Anduix
Cancer Discovery. 2018-08-01

Journal Articles

Isolation and Characterization of NY-ESO-1–Specific T Cell Receptors Restricted on Various MHC Molecules
Antoni Ribas, Proceedings of the National Academy of Sciences
Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based Immunotherapy
Jonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Antoni Ribas, Jennifer A Wargo, Sumit K Subudhi, Padmanee Sharma, Clinical Cancer Research
Reprogramming Human T Cell Function and Specificity with Non-Viral Genome Targeting
Neil Romberg, Antoni Ribas, Michael R Lee, Ruby Yu, Gary M Kupfer, Julia Carnevale, Jonathan H Esensten, P Jonathan Li, Han Li, Kevan C Herold, Alexander Marson, Nature
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell Populations
Zeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research
IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System
Kenneth Cornetta, Antoni Ribas, Gay M Crooks, Donald B Kohn, Clinical Cancer Research
Join now to see all

Lectures

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naÃ¯ve to anti-PD-1 therapy.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients with BRAFV600-Mutated Metastatic Melanoma
International Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/24/2012
International Society for Biological Therapy of Cancer (iSBTc): Annual Meeting
International Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/26/2012

Authored Content

Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018

Press Mentions

UCLA and Parker Institute Continue Collaboration to Advance Next-Generation Cancer ImmunotherapiesOctober 16th, 2024
Cancer Spread to Jimmy Carter's Brain 9 Years Ago. Here's How He's Lived so LongSeptember 30th, 2024
Cancer Treatment Extended Jimmy Carter’s Life Before His 100th BirthdaySeptember 30th, 2024
Join now to see all

Other Languages

Spanish

AntoniRibasMD

Dr. Ribas is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Authored Content

Press Mentions

Other Languages

Viewing the full profile is available to verified healthcare professionals only.